Subscribe today to receive our latest blogs, articles, podcasts and more.
Insights
Participating in open and frank conversations can be a catalyst for both positive change and a better industry. As we share our perspective you will find:
- Relevant and timely industry information
- Medication trends, and their impact
- Case studies, and the results of their related projects
- Special-subject on-demand webinars
Articles, blogs and podcasts
Sharing information with the industry is an important part of our mission. Our subject matter experts translate today’s news into comprehensive informational pieces to help you better understand the impact of a recent industry update, trend, or issue.
|
July 14, 2022 · Clinical Team
Effective June 30, 2022, Zelnorm 6 mg tablet will no longer be produced and marketed in the United States, as announced by its manufacturer, Alfasigma USA, Inc. Read more... |
|
July 06, 2022 · Clinical Team
The U.S. Food and Drug Administration (FDA) approved Quviviq (daridorexant) 25 mg and 50 mg tablets on January 10, 2022. Manufactured by Idorsia Pharmaceuticals US Inc., this sedative/hypnotic is indicated for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. Read more... |
|
June 24, 2022 · Medicare Insights Team
On June 6, 2022, the Supreme Court ruled 7-2 in Gallardo v. Marstiller that Florida Medicaid was permitted reimbursement from a settlement involving a permanently disabled woman. The woman, Ms. Gallardo, was involved in a catastrophic injury when she was hit by a truck while exiting a school bus. Florida Medicaid previously paid $862,688.77 in medical expenses and was expected to continue paying for future medical expenses related to this incident. Read more... |
|
June 23, 2022 · Public Policy & Regulatory Affairs Team
Read more... |
|
May 31, 2022 · Public Policy & Regulatory Affairs Team
The Policy Guys get a wake-up call about the recent updates to the Work Comp Medicare Set-Aside Arrangement Reference Guide published by CMS on March 15, 2022. Michael Flower and Melanie Carrozza of the Optum Settlement group join our Policy duo to review MSAs, Non-CMS approved MSAs and CMPs. Click to learn about each of these acronyms and more! Read more... |
|
|
May 31, 2022 · Public Policy & Regulatory Affairs Team
Read more... |
Page 1 of 17
